699 related articles for article (PubMed ID: 20205482)
21. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
[TBL] [Abstract][Full Text] [Related]
22. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
23. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
24. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
25. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Basile J
Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987
[TBL] [Abstract][Full Text] [Related]
26. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
27. Dapagliflozin: an emerging treatment option in type 2 diabetes.
Kipnes M
Expert Opin Investig Drugs; 2009 Mar; 18(3):327-34. PubMed ID: 19243283
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH; Leung PS
Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516
[TBL] [Abstract][Full Text] [Related]
30. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
31. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.
Chan HW; Ashan B; Jayasekera P; Collier A; Ghosh S
Diabetes Metab Syndr; 2012; 6(4):224-8. PubMed ID: 23199545
[TBL] [Abstract][Full Text] [Related]
32. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Plosker GL
Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
[TBL] [Abstract][Full Text] [Related]
33. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Freeman JS
Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
[TBL] [Abstract][Full Text] [Related]
34. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
35. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
[TBL] [Abstract][Full Text] [Related]
36. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
37. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Pérez López G; González Albarrán O; Cano Megías M
Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210
[TBL] [Abstract][Full Text] [Related]
38. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Handelsman Y
Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
[TBL] [Abstract][Full Text] [Related]
39. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
40. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
